Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) EBITDA (2016 - 2025)

Historic EBITDA for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to $4.9 million.

  • Sanara MedTech's EBITDA rose 9146.54% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 4879.1%. This contributed to the annual value of $2.7 million for FY2024, which is 201502.59% up from last year.
  • Latest data reveals that Sanara MedTech reported EBITDA of $4.9 million as of Q3 2025, which was up 9146.54% from $2.7 million recorded in Q2 2025.
  • Sanara MedTech's 5-year EBITDA high stood at $4.9 million for Q3 2025, and its period low was -$3.3 million during Q4 2021.
  • For the 5-year period, Sanara MedTech's EBITDA averaged around -$561039.1, with its median value being -$1.0 million (2021).
  • Data for Sanara MedTech's EBITDA shows a peak YoY increase of 86086.88% (in 2024) and a maximum YoY decrease of 63560.14% (in 2024) over the last 5 years.
  • Over the past 5 years, Sanara MedTech's EBITDA (Quarter) stood at -$3.3 million in 2021, then grew by 9.14% to -$3.0 million in 2022, then soared by 114.88% to $448909.0 in 2023, then tumbled by 635.6% to -$2.4 million in 2024, then surged by 304.14% to $4.9 million in 2025.
  • Its EBITDA was $4.9 million in Q3 2025, compared to $2.7 million in Q2 2025 and $657969.0 in Q1 2025.